<DOC>
	<DOCNO>NCT00784745</DOCNO>
	<brief_summary>The purpose study examine whether causal relationship insulin resistance and/or glucose intolerance development defect incretin effect .</brief_summary>
	<brief_title>Is Insulin Resistance and/or Glucose Intolerance Pathogenetic Development Reduced Incretin Effect</brief_title>
	<detailed_description>In study go examine incretin effect development insulin resistance and/or glucose intolerance . The incretin effect increase insulin response see oral appose intravenous glucose challenge identical plasma glucose profile . This insulin enhance effect greatly reduce type 2 diabetes . Since development type 2 diabetes precede insulin resistance glucose intolerance want examine incretin effect early stage type 2 diabetes . To , want induce insulin resistance and/or glucose intolerance . This achieve 5 day treatment dexamethasone . The incretin effect study examine 3 investigation prior treatment 3 day follow treatment . Day 1 : Oral glucose challenge 75 g glucose . The subject ask drink 75g glucose suspend 300mL water . During 4 hour test , draw blood various time study determine concentration : Glucose , GLP-1 , GIP , Glucagon , Insulin c-peptide . Day 2 : Intravenous glucose We duplicate glucose curve obtain day 1 . We also draw blood test end day 1 . Day 3 : Mixed meal . The subject serve mixed meal . During 4 hour test , draw blood examine response standardize meal . The test involve sample blood describe day .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<criteria>Caucasians &gt; 20 year Normal glucose tolerance assess WHO criteria First degree relative least 1 second degree relative type 2 diabetes Normal haemoglobin Informed consent Liver disease ( ALAT/ASAT &gt; 2 time normal value ) Kidney disease ( Screatinin &gt; 130uM and/or albuminuria ) Heart disease ( NYHA II , III IV ) Treatment medicine pause Pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>incretin effect</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>GLP-1</keyword>
	<keyword>GIP</keyword>
	<keyword>dexamethasone</keyword>
</DOC>